Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Mar 20, 2024 |
referred to health |
Assembly Bill A9535
2023-2024 Legislative Session
Sponsored By
STECK
Current Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
2023-A9535 (ACTIVE) - Details
- Current Committee:
- Assembly Health
- Law Section:
- Public Health Law
- Laws Affected:
- Add Art 2-A Title IV §§285 - 288, Pub Health L
2023-A9535 (ACTIVE) - Summary
Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.
2023-A9535 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 9535 I N A S S E M B L Y March 20, 2024 ___________ Introduced by M. of A. STECK -- read once and referred to the Committee on Health AN ACT to amend the public health law, in relation to establishing a generic drug research and development laboratory and production facil- ity and the empire state biosimilar insulin initiative THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Article 2-A of the public health law is amended by adding a new title IV to read as follows: TITLE IV NEW YORK AFFORDABLE DRUG MANUFACTURING ACT SECTION 285. DEFINITIONS. 286. GENERIC DRUG RESEARCH AND DEVELOPMENT LABORATORY AND PRODUCTION FACILITY; EMPIRE STATE BIOSIMILAR INSULIN INITIATIVE. 287. PARTNERSHIPS; PRODUCTION AND DISTRIBUTION OF PRESCRIPTION DRUGS. 288. PROPRIETARY INFORMATION. § 285. DEFINITIONS. 1. FOR THE PURPOSES OF THIS TITLE, THE FOLLOWING TERMS SHALL HAVE THE FOLLOWING MEANINGS: (A) "GENERIC DRUG" SHALL MEAN A DRUG THAT IS APPROVED PURSUANT TO SUBDIVISION (J) OF SECTION 355 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT (21 U.S.C. SEC. 301 ET SEQ.), OR A BIOSIMILAR, AS DEFINED UNDER THE FEDERAL PUBLIC HEALTH SERVICE ACT (42 U.S.C. SEC. 262). (B) "PARTNERSHIPS" SHALL INCLUDE, BUT NOT BE LIMITED TO, AGREEMENTS FOR THE PROCUREMENT OF GENERIC PRESCRIPTION DRUGS BY WAY OF CONTRACTS OR PURCHASING BY A PAYER, STATE GOVERNMENTAL AGENCY, GROUP PURCHASING ORGANIZATION, NONPROFIT ORGANIZATION, OR OTHER ENTITY. § 286. GENERIC DRUG RESEARCH AND DEVELOPMENT LABORATORY AND PRODUCTION FACILITY; EMPIRE STATE BIOSIMILAR INSULIN INITIATIVE. 1. (A) THE DEPART- MENT SHALL ESTABLISH A GENERIC DRUG RESEARCH AND DEVELOPMENT LABORATORY AND PRODUCTION FACILITY WITHIN THE UNIVERSITY OF THE STATE OF NEW YORK SYSTEM. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD13501-01-3
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.